Document is current
Any future updates will be listed below
-
Authors
Kramarenko, Daria R.
Jurgens, Sean J.
Pinto, Yigal M.
Bezzina, Connie R.
Amin, Ahmad S.
-
Funding
Funding for this research was provided by:
Dutch Heart Foundation (03-007-2022-0035, CVON 2018-30 PREDICT2)
Pathfinder Cardiogenomics programme of the European Innovation Council of the European Union
- License Information
-
More Information
Article History
Accepted: 15 April 2025
First Online: 14 May 2025
Declarations
:
: No animal or human subjects by the authors were used in this study.
: A.S. Amin is supported by the EU4H-Programme of the European Union (support for the ERN GUARD-Heart project) and Novo Nordisk, has received consultancy fees from BioMarin and Tenaya Therapeutics, reports speakers’ fees from Bristol Myers Squibb and Pfizer, and has participated on an Advisory Board for Bristol Myers Squibb on mavacamten use in the Netherlands. D.R. Kramarenko and Y.M. Pinto were supported by funding from the PSIDER programme of the Netherlands Organisation for Health Research and Development (ZonMW; project 40-46800-98-018). Y.M. Pinto discloses that he receives fees from spin-off companies that develop therapies for cardiomyopathy and that he is an advisor to Forbion capital (he also has stock and IP rights), a VC investing in life sciences companies, none of which relates to the contents of this review. Y.M. Pinto also reports consulting fees from ARMGO pharma and Phlox Therapeutics. Y.M. Pinto also has patents on shRNAs for dcm. C. Bezzina reports consulting fees from Tenaya Therapeutics, and she is a member of the European Cardiac Arrhythmia Genetics (ECGen) Focus of the European Heart Rhythm Society. The other authors declare that they have no conflict of interest.
